cetuximab + trametinib + vemurafenib

Cetuximab + trametinib + vemurafenib is an investigational combination therapy composed of three targeted agents, each with a distinct mechanism of action. Cetuximab is a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), thereby blocking downstream signaling pathways involved in cell proliferation and survival. Trametinib is a small molecule inhibitor targeting MEK1/2, key kinases in the MAPK/ERK pathway downstream of BRAF and EGFR. Vemurafenib is a selective inhibitor of BRAF V600E-mutant kinase, which drives oncogenic signaling in various cancers, particularly melanoma and colorectal cancer with BRAF V600E mutations. The rationale for combining these agents lies in overcoming resistance mechanisms seen with monotherapy or dual therapy by simultaneously inhibiting multiple nodes within the MAPK pathway and EGFR axis. This triple regimen has been explored primarily for advanced solid tumors harboring BRAF V600E mutations, especially metastatic colorectal cancer (mCRC), though it remains investigational and not standard-of-care[2][4][5].

Other names

cetuximab plus dabrafenib plus trametinibcetuximab/dabrafenib/trametinib